Department of Respirology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou 510120, China.
Department of Pathology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou 510120, China.
Cancer Treat Res Commun. 2021;29:100474. doi: 10.1016/j.ctarc.2021.100474. Epub 2021 Oct 12.
Hepatoid adenocarcinoma of the lung (HAL) is a rare form of lung cancer, which is characterized by its morphologic hepatoid features. The clinical characteristics and prognosis of this rare form of lung cancer remain obscure.
The clinical courses of four cases of HAL were reported. A literature search was performed up to December 31, 2020, using the electronic databases PubMed and Web of Science.
Including the present 4 cases, a total of 42 cases of HAL have been reported in the literature. The median age was 58.5 years old (range, 36-73 years). 36 (85.7%) patients were male. 26 (61.9%) patients had a history of smoking, the median amount of smoking was 40 pack years (range, 8-180). The most common site of the primary tumor was the right upper lobe (22 cases, 52.3%) and the left upper lobe (10 cases, 23.8%). 21 patients (50%) had pretreatment serum AFP levels higher than the upper limit, and 4 patients (9.5%) had normal pretreatment serum AFP levels. Treatment of HAL included surgery, chemotherapy, radiotherapy, tyrosine kinase inhibitors (TKIs), anti-angiogenesis therapy, and anti-PD-1/PD-L1 monoclonal antibody. Overall, the prognosis of HAL was poor, with median overall survival (OS) of 14 months.
HAL is an aggressive tumor, with a poor prognosis and male predominance, which tends to occur in heavy smokers and affects the right upper lobe of the lung.
肝样腺癌（Hepatoid adenocarcinoma of the lung，HAL）是一种罕见的肺癌，其特征为具有肝样形态学特征。这种罕见肺癌的临床特征和预后仍不清楚。
报告了 4 例 HAL 患者的临床病程。截至 2020 年 12 月 31 日，使用 PubMed 和 Web of Science 电子数据库进行了文献检索。
包括本研究的 4 例病例，文献中共报道了 42 例 HAL。中位年龄为 58.5 岁（范围为 36-73 岁）。36 例（85.7%）患者为男性。26 例（61.9%）患者有吸烟史，中位吸烟量为 40 包年（范围为 8-180）。原发肿瘤最常见的部位是右肺上叶（22 例，52.3%）和左肺上叶（10 例，23.8%）。21 例（50%）患者治疗前血清 AFP 水平高于正常值上限，4 例（9.5%）患者治疗前血清 AFP 水平正常。HAL 的治疗包括手术、化疗、放疗、酪氨酸激酶抑制剂（TKIs）、抗血管生成治疗和抗 PD-1/PD-L1 单克隆抗体。总体而言，HAL 的预后较差，中位总生存期（Overall survival，OS）为 14 个月。
HAL 是一种侵袭性肿瘤，预后不良，男性居多，易发生于重度吸烟者，且常影响右上肺。
